Annual CFO
-$5.01 M
+$5.90 M+54.05%
December 31, 2023
Summary
- As of February 10, 2025, ABIO annual cash flow from operations is -$5.01 million, with the most recent change of +$5.90 million (+54.05%) on December 31, 2023.
- During the last 3 years, ABIO annual CFO has risen by +$2.71 million (+35.09%).
Performance
ABIO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFO
-$2.63 M
-$1.11 M-72.38%
June 30, 2024
Summary
- As of February 10, 2025, ABIO quarterly cash flow from operations is -$2.63 million, with the most recent change of -$1.11 million (-72.38%) on June 30, 2024.
- Over the past year, ABIO quarterly CFO has dropped by -$1.58 million (-149.43%).
Performance
ABIO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
-$6.89 M
-$1.94 M-39.22%
June 30, 2024
Summary
- As of February 10, 2025, ABIO TTM cash flow from operations is -$6.89 million, with the most recent change of -$1.94 million (-39.22%) on June 30, 2024.
- Over the past year, ABIO TTM CFO has dropped by -$1.87 million (-37.36%).
Performance
ABIO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ABIO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +54.0% | -149.4% | -37.4% |
| 3 y3 years | +35.1% | +45.9% | +59.0% |
| 5 y5 years | +39.2% | +45.9% | +59.0% |
ABIO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +274.2% | +279.5% | +87.8% | +39.2% | +172.4% |
| 5 y | 5-year | +4.4% | +274.2% | +279.5% | +98.4% | +44.3% | +172.4% |
| alltime | all time | +23.0% | +1077.4% | -113.3% | +1051.6% | +305.1% | +950.2% |
ARCA Biopharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2024 | - | -$2.63 M(+72.4%) | -$6.89 M(+39.2%) |
| Mar 2024 | - | -$1.53 M(+44.7%) | -$4.95 M(-1.3%) |
| Dec 2023 | -$5.01 M(-54.1%) | -$1.06 M(-36.7%) | -$5.01 M(-8.0%) |
| Sep 2023 | - | -$1.67 M(+140.5%) | -$5.45 M(-13.2%) |
| Jun 2023 | - | -$694.00 K(-56.5%) | -$6.28 M(-23.5%) |
| Mar 2023 | - | -$1.59 M(+6.8%) | -$8.21 M(-24.8%) |
| Dec 2022 | -$10.91 M(-41.8%) | -$1.49 M(-40.2%) | -$10.91 M(-24.0%) |
| Sep 2022 | - | -$2.50 M(-4.7%) | -$14.37 M(-14.2%) |
| Jun 2022 | - | -$2.62 M(-39.0%) | -$16.74 M(-6.2%) |
| Mar 2022 | - | -$4.30 M(-13.1%) | -$17.84 M(-4.9%) |
| Dec 2021 | -$18.76 M(+142.9%) | -$4.95 M(+1.6%) | -$18.76 M(+11.6%) |
| Sep 2021 | - | -$4.87 M(+30.9%) | -$16.81 M(+20.6%) |
| Jun 2021 | - | -$3.72 M(-28.8%) | -$13.94 M(+23.8%) |
| Mar 2021 | - | -$5.22 M(+74.5%) | -$11.26 M(+45.8%) |
| Dec 2020 | -$7.72 M(+60.9%) | -$3.00 M(+49.6%) | -$7.72 M(+31.2%) |
| Sep 2020 | - | -$2.00 M(+92.1%) | -$5.89 M(+23.4%) |
| Jun 2020 | - | -$1.04 M(-38.2%) | -$4.77 M(-3.0%) |
| Mar 2020 | - | -$1.69 M(+45.6%) | -$4.92 M(+2.5%) |
| Dec 2019 | -$4.80 M(-41.8%) | -$1.16 M(+30.6%) | -$4.80 M(-3.7%) |
| Sep 2019 | - | -$887.00 K(-25.5%) | -$4.99 M(-12.1%) |
| Jun 2019 | - | -$1.19 M(-24.0%) | -$5.67 M(-15.8%) |
| Mar 2019 | - | -$1.57 M(+16.6%) | -$6.74 M(-18.3%) |
| Dec 2018 | -$8.24 M(-52.8%) | -$1.34 M(-14.8%) | -$8.24 M(-25.7%) |
| Sep 2018 | - | -$1.58 M(-30.1%) | -$11.10 M(-17.8%) |
| Jun 2018 | - | -$2.25 M(-26.6%) | -$13.49 M(-16.7%) |
| Mar 2018 | - | -$3.07 M(-26.8%) | -$16.20 M(-7.3%) |
| Dec 2017 | -$17.47 M(+16.6%) | -$4.20 M(+5.6%) | -$17.47 M(+2.1%) |
| Sep 2017 | - | -$3.97 M(-19.8%) | -$17.12 M(+1.4%) |
| Jun 2017 | - | -$4.96 M(+14.1%) | -$16.88 M(+9.3%) |
| Mar 2017 | - | -$4.34 M(+13.1%) | -$15.45 M(+3.1%) |
| Dec 2016 | -$14.99 M(+42.3%) | -$3.84 M(+2.8%) | -$14.99 M(+8.9%) |
| Sep 2016 | - | -$3.74 M(+6.0%) | -$13.77 M(+10.7%) |
| Jun 2016 | - | -$3.53 M(-9.2%) | -$12.43 M(+10.0%) |
| Mar 2016 | - | -$3.88 M(+48.2%) | -$11.30 M(+7.3%) |
| Dec 2015 | -$10.53 M(+12.0%) | -$2.62 M(+9.1%) | -$10.53 M(+7.6%) |
| Sep 2015 | - | -$2.40 M(+0.1%) | -$9.79 M(+3.4%) |
| Jun 2015 | - | -$2.40 M(-22.9%) | -$9.47 M(+7.2%) |
| Mar 2015 | - | -$3.11 M(+65.7%) | -$8.83 M(-6.1%) |
| Dec 2014 | -$9.41 M(+77.9%) | -$1.88 M(-9.5%) | -$9.41 M(+0.1%) |
| Sep 2014 | - | -$2.08 M(+17.8%) | -$9.40 M(+4.5%) |
| Jun 2014 | - | -$1.76 M(-52.2%) | -$9.00 M(+9.6%) |
| Mar 2014 | - | -$3.69 M(+97.0%) | -$8.21 M(+55.3%) |
| Dec 2013 | -$5.29 M(+29.7%) | -$1.87 M(+11.7%) | -$5.29 M(+29.4%) |
| Sep 2013 | - | -$1.68 M(+71.7%) | -$4.09 M(+28.3%) |
| Jun 2013 | - | -$976.00 K(+27.7%) | -$3.19 M(-0.0%) |
| Mar 2013 | - | -$764.00 K(+14.0%) | -$3.19 M(-21.9%) |
| Dec 2012 | -$4.08 M(-41.4%) | -$670.00 K(-13.5%) | -$4.08 M(-12.2%) |
| Sep 2012 | - | -$775.00 K(-20.7%) | -$4.64 M(-16.2%) |
| Jun 2012 | - | -$977.00 K(-41.0%) | -$5.54 M(-16.9%) |
| Mar 2012 | - | -$1.66 M(+34.0%) | -$6.67 M(-4.1%) |
| Dec 2011 | -$6.96 M(-16.4%) | -$1.24 M(-26.3%) | -$6.96 M(+1.4%) |
| Sep 2011 | - | -$1.68 M(-20.5%) | -$6.87 M(-4.7%) |
| Jun 2011 | - | -$2.11 M(+8.6%) | -$7.20 M(+1.0%) |
| Mar 2011 | - | -$1.94 M(+69.9%) | -$7.13 M(-14.3%) |
| Dec 2010 | -$8.32 M | -$1.14 M(-43.2%) | -$8.32 M(-17.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2010 | - | -$2.01 M(-1.2%) | -$10.09 M(-45.7%) |
| Jun 2010 | - | -$2.04 M(-35.0%) | -$18.58 M(-32.2%) |
| Mar 2010 | - | -$3.13 M(+7.7%) | -$27.40 M(-34.3%) |
| Dec 2009 | -$41.73 M(+126.8%) | -$2.91 M(-72.3%) | -$41.73 M(+119.7%) |
| Sep 2009 | - | -$10.50 M(-3.2%) | -$18.99 M(-51.1%) |
| Jun 2009 | - | -$10.85 M(-37.9%) | -$38.82 M(+99.4%) |
| Mar 2009 | - | -$17.46 M(-188.1%) | -$19.47 M(+5.8%) |
| Dec 2008 | -$18.40 M(-60.0%) | $19.83 M(-165.4%) | -$18.40 M(-64.5%) |
| Sep 2008 | - | -$30.33 M(-456.9%) | -$51.88 M(+125.0%) |
| Jun 2008 | - | $8.50 M(-151.8%) | -$23.06 M(-49.0%) |
| Mar 2008 | - | -$16.39 M(+20.1%) | -$45.17 M(-1.7%) |
| Dec 2007 | -$45.96 M(+24.0%) | -$13.65 M(+800.3%) | -$45.96 M(-2.8%) |
| Sep 2007 | - | -$1.52 M(-88.9%) | -$47.28 M(-32.3%) |
| Jun 2007 | - | -$13.62 M(-20.7%) | -$69.80 M(-3.5%) |
| Mar 2007 | - | -$17.18 M(+14.7%) | -$72.33 M(+95.2%) |
| Dec 2006 | -$37.06 M(-37.2%) | -$14.97 M(-37.7%) | -$37.06 M(-6.0%) |
| Sep 2006 | - | -$24.04 M(+48.9%) | -$39.43 M(+26.6%) |
| Jun 2006 | - | -$16.14 M(-189.2%) | -$31.13 M(+8.9%) |
| Mar 2006 | - | $18.09 M(-204.4%) | -$28.58 M(-51.6%) |
| Dec 2005 | -$59.03 M(+17.8%) | -$17.34 M(+10.1%) | -$59.03 M(-2.5%) |
| Sep 2005 | - | -$15.74 M(+15.8%) | -$60.52 M(+10.5%) |
| Jun 2005 | - | -$13.60 M(+10.0%) | -$54.77 M(+2.1%) |
| Mar 2005 | - | -$12.36 M(-34.3%) | -$53.64 M(+7.0%) |
| Dec 2004 | -$50.11 M(+11.2%) | -$18.82 M(+88.4%) | -$50.11 M(+17.1%) |
| Sep 2004 | - | -$9.99 M(-19.9%) | -$42.79 M(+1.9%) |
| Jun 2004 | - | -$12.47 M(+41.3%) | -$41.99 M(-3.1%) |
| Mar 2004 | - | -$8.83 M(-23.3%) | -$43.33 M(-3.9%) |
| Dec 2003 | -$45.07 M(+45.8%) | -$11.50 M(+25.3%) | -$45.07 M(+10.0%) |
| Sep 2003 | - | -$9.18 M(-33.5%) | -$40.96 M(+5.0%) |
| Jun 2003 | - | -$13.81 M(+30.7%) | -$39.01 M(+17.9%) |
| Mar 2003 | - | -$10.57 M(+42.8%) | -$33.08 M(+7.0%) |
| Dec 2002 | -$30.91 M(+40.0%) | -$7.40 M(+2.3%) | -$30.91 M(+16.0%) |
| Sep 2002 | - | -$7.23 M(-8.2%) | -$26.63 M(-1.7%) |
| Jun 2002 | - | -$7.88 M(-6.2%) | -$27.10 M(+5.4%) |
| Mar 2002 | - | -$8.40 M(+168.8%) | -$25.72 M(+16.5%) |
| Dec 2001 | -$22.08 M(+5.2%) | -$3.12 M(-59.4%) | -$22.08 M(-19.1%) |
| Sep 2001 | - | -$7.70 M(+18.6%) | -$27.31 M(+2.2%) |
| Jun 2001 | - | -$6.50 M(+36.4%) | -$26.71 M(-0.9%) |
| Mar 2001 | - | -$4.76 M(-43.0%) | -$26.96 M(+28.5%) |
| Dec 2000 | -$20.99 M(+61.4%) | -$8.35 M(+17.6%) | -$20.99 M(+77.3%) |
| Sep 2000 | - | -$7.10 M(+5.3%) | -$11.83 M(+38.7%) |
| Jun 2000 | - | -$6.74 M(-656.4%) | -$8.53 M(+74.5%) |
| Mar 2000 | - | $1.21 M(+51.5%) | -$4.89 M(-62.4%) |
| Dec 1999 | -$13.00 M(+11.1%) | $800.00 K(-121.1%) | -$13.00 M(-9.7%) |
| Sep 1999 | - | -$3.80 M(+22.6%) | -$14.40 M(-7.1%) |
| Jun 1999 | - | -$3.10 M(-55.1%) | -$15.50 M(-15.8%) |
| Mar 1999 | - | -$6.90 M(+1050.0%) | -$18.40 M(+57.3%) |
| Dec 1998 | -$11.70 M(+44.4%) | -$600.00 K(-87.8%) | -$11.70 M(-24.0%) |
| Sep 1998 | - | -$4.90 M(-18.3%) | -$15.40 M(+23.2%) |
| Jun 1998 | - | -$6.00 M(+2900.0%) | -$12.50 M(+89.4%) |
| Mar 1998 | - | -$200.00 K(-95.3%) | -$6.60 M(-18.5%) |
| Dec 1997 | -$8.10 M(+88.4%) | -$4.30 M(+115.0%) | -$8.10 M(+113.2%) |
| Sep 1997 | - | -$2.00 M(+1900.0%) | -$3.80 M(+111.1%) |
| Jun 1997 | - | -$100.00 K(-94.1%) | -$1.80 M(+5.9%) |
| Mar 1997 | - | -$1.70 M | -$1.70 M |
| Dec 1996 | -$4.30 M | - | - |
FAQ
- What is ARCA biopharma annual cash flow from operations?
- What is the all time high annual CFO for ARCA biopharma?
- What is ARCA biopharma annual CFO year-on-year change?
- What is ARCA biopharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for ARCA biopharma?
- What is ARCA biopharma quarterly CFO year-on-year change?
- What is ARCA biopharma TTM cash flow from operations?
- What is the all time high TTM CFO for ARCA biopharma?
- What is ARCA biopharma TTM CFO year-on-year change?
What is ARCA biopharma annual cash flow from operations?
The current annual CFO of ABIO is -$5.01 M
What is the all time high annual CFO for ARCA biopharma?
ARCA biopharma all-time high annual cash flow from operations is -$4.08 M
What is ARCA biopharma annual CFO year-on-year change?
Over the past year, ABIO annual cash flow from operations has changed by +$5.90 M (+54.05%)
What is ARCA biopharma quarterly cash flow from operations?
The current quarterly CFO of ABIO is -$2.63 M
What is the all time high quarterly CFO for ARCA biopharma?
ARCA biopharma all-time high quarterly cash flow from operations is $19.83 M
What is ARCA biopharma quarterly CFO year-on-year change?
Over the past year, ABIO quarterly cash flow from operations has changed by -$1.58 M (-149.43%)
What is ARCA biopharma TTM cash flow from operations?
The current TTM CFO of ABIO is -$6.89 M
What is the all time high TTM CFO for ARCA biopharma?
ARCA biopharma all-time high TTM cash flow from operations is -$1.70 M
What is ARCA biopharma TTM CFO year-on-year change?
Over the past year, ABIO TTM cash flow from operations has changed by -$1.87 M (-37.36%)